^
    Back
    Association details:
    Biomarker:PD-L1 elevation
    Cancer:HER2 Positive Breast Cancer
    Drug:Herceptin (trastuzumab) (HER2 inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: B - Late Trials
    New
    Source:
    Cancer
    Title:

    Higher serum PD-L1 level predicts increased overall survival with lapatinib versus trastuzumab in the CCTG MA.31 phase 3 trial

    Published date:
    09/10/2020
    Excerpt:
    ...within the trastuzumab arm, a higher continuous pretreatment serum PD‐L1 level was significant for shorter OS (hazard ratio [HR], 3.85; P = .04)...
    DOI:
    10.1002/cncr.33149